'Hf hospitalization' presentation slideshows

Advances in the Management of Heart Failure

Advances in the Management of Heart Failure. Daniel P. Fishbein, M.D . Professor of Medicine Medical Director, Heart Failure and Cardiac Transplantation University of Washington Medical Center. The Scope of the Problem - CHF. 5 million patients with CHF (10 million by 2020)

2.76k views • 149 slides

Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE

575 views • 43 slides

The Basic Science of Heart Failure: Dual-Action Molecules in Perspective

The Basic Science of Heart Failure: Dual-Action Molecules in Perspective. Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy. Renin-Angiotensin-Aldosterone System. RAAS Inhibition in CHF.

1.26k views • 40 slides

Top Tips in Evidence-Based Care for HFrEF

Top Tips in Evidence-Based Care for HFrEF. Typical Patient With HFrEF. Key Therapies in HFrEF: How Do They Work?. 2016 ESC HF Guidelines: Next...Add an MRA and ARNI. Principles for Successful Treatment for HF. Starting and Titrating Drug Therapies in HFrEF.

299 views • 29 slides

New Approaches to Monitoring Heart Failure Before Symptoms Appear

New Approaches to Monitoring Heart Failure Before Symptoms Appear. William T. Abraham, MD, FACP, FACC Professor of Medicine Chief, Division of Cardiovascular Medicine Associate Director, Davis Heart & Lung Research Institute The Ohio State University Columbus, Ohio.

381 views • 27 slides

Heart Failure and Secondary Mitral Regurgitation: Echocardiographic Outcomes from the COAPT trial

Heart Failure and Secondary Mitral Regurgitation: Echocardiographic Outcomes from the COAPT trial. Federico M. Asch, MD Director, Echocardiographic Core Lab MedStar Health Research Institute On behalf of Gregg W. Stone, Michael Mack, Neil J Weissman and the COAPT Investigators.

320 views • 27 slides

Disease Management, Advance Directives, and End-of-Life Care in Heart Failure

Disease Management, Advance Directives, and End-of-Life Care in Heart Failure. HFSA 2010 Recommendations. 1 of 2 HFSA 2010 Practice Guideline Patient Education. Recommendation 8.1 (1 of 2)

558 views • 26 slides

Angiotensin Receptor N eprilysin Inhibition (ARNI): LCZ696

Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial.

250 views • 24 slides

Epidemiology of Diabetes and Heart Failure

Epidemiology of Diabetes and Heart Failure. David McFadden M.D. Mayo Clinic. Heart failure (HF) affects ? 5 million persons and is responsible for ? 250,000 deaths in the United States annually.

353 views • 23 slides

Disclosures

533 views • 22 slides

Combined Heart Failure Device Diagnostics Identify Patients at Higher Risk of Subsequent Heart Failure Hospitalization

Combined Heart Failure Device Diagnostics Identify Patients at Higher Risk of Subsequent Heart Failure Hospitalizations: Results from PARTNERS HF Study. on behalf of the PARTNERS HF Study Investigators. David J. Whellan, MD FACC Associate Professor of Medicine

504 views • 22 slides

Predictors of HF Hospitalization

Predictors of HF Hospitalization. ESCAPE Trial Pulmonary Artery Catheterization Effectiveness. Pulmonary Artery Pressure Measurement System. CHAMPION Primary Safety End Points. CHAMPION Trial Design.

315 views • 22 slides

Background

284 views • 13 slides

ADA/EASD Position Statement: Approach to Hyperglycemia Management

ADA/EASD Position Statement: Approach to Hyperglycemia Management. ADA/EASD Position Statement: Antihyperglycemic Therapy in T2DM. SGLT2 Inhibitors: Weight Reduction in Randomized Trials as Add-On to Metformin. SGLT2 Inhibitors: Glycemic Control Comparison as Add-On to Metformin.

124 views • 8 slides

Recurrence of HF hospitalization Total-time approach

Recurrence of HF hospitalization Total-time approach. Hazard ratio. p -value. Ivabradine (n=3241). Placebo (n=3264). First hospitalization. 514 (16%). 672 (21%). p<0.001. 0.75. Second hospitalization. 189 (6%). p<0.001. 283 (9%). 0.66. Third hospitalization. 90 (3%).

133 views • 1 slides

Patients 3-10 days post ACS without HF/LVSD but ? natriuretic peptides

N=1101. Patients 3-10 days post ACS without HF/LVSD but ? natriuretic peptides. Standard Medical Therapy. NT- proBNP & Aldosterone. Blinded Therapy. Placebo. Aliskiren. Valsartan. Valsartan /Aliskiren. 4 wks. Dose up-titration over 2 weeks. NT-proBNP.

120 views • 1 slides